The results of a new study revealed that the property (known as the commercial names is Monjoro and Zipond) helps to lose weight significantly and sustainable after using it once a week for at least 3 years for adults with weight gain or obesity who are not with diabetes.
The preliminary results of the study on the European Association for the Study of obesity were presented on April 11, 2025. The remaining details of the study will be revealed within the conference that the association will hold in the period 11-14 May this year in Malaga, Spain.
The study was supervised by Dr. Luka Bozeto of the Italian University of Badova, in cooperation with ELI Lilly, manufactured for the Terzepatide. Dr. Bouzito stated that the results of the study proved that the response to the drug varies from person to person, as the two categories most respond to the drug are women and adults who suffer from weight gain or obesity without diabetes.
The results of the participants who adhered to take the drug for 3 years were divided into 3 categories, the first category lost 10% of its weight only, which is the fastest category to the stage of steadfastness. The second category lost 20% of its original weight before reaching stability in weight.
Lugging in the long run
The third category is the most responsive to the property, as it lost the largest weight rate, which is 30%, in addition to that it was the slower in reaching the stage of stability. And formed women and adults with diabetes, the majority of the third Series.
Most of the participants in the study reached the stage of steadfastness 6-12 months after they started taking the property, but they were able to maintain their new weight. The results of this study confirm the effectiveness of injecting weight in the long run if it is constantly consumed.
The study did not reveal any new health risks of the Terzopatid injection, but confirmed that there are some common side effects as in previous studies such as feeling nauseous, diarrhea or constipation.